247 related articles for article (PubMed ID: 32611550)
1. Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9.
Itkonen HM; Poulose N; Steele RE; Martin SES; Levine ZG; Duveau DY; Carelli R; Singh R; Urbanucci A; Loda M; Thomas CJ; Mills IG; Walker S
Mol Cancer Res; 2020 Oct; 18(10):1512-1521. PubMed ID: 32611550
[TBL] [Abstract][Full Text] [Related]
2. O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage.
Gondane A; Girmay S; Helevä A; Pallasaho S; Loda M; Itkonen HM
J Biomed Sci; 2022 Feb; 29(1):13. PubMed ID: 35164752
[TBL] [Abstract][Full Text] [Related]
3. O-GlcNAc transferase maintains metabolic homeostasis in response to CDK9 inhibition.
Gondane A; Poulose N; Walker S; Mills IG; Itkonen HM
Glycobiology; 2022 Aug; 32(9):751-759. PubMed ID: 35708495
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism.
Itkonen HM; Gorad SS; Duveau DY; Martin SE; Barkovskaya A; Bathen TF; Moestue SA; Mills IG
Oncotarget; 2016 Mar; 7(11):12464-76. PubMed ID: 26824323
[TBL] [Abstract][Full Text] [Related]
5. High OGT activity is essential for MYC-driven proliferation of prostate cancer cells.
Itkonen HM; Urbanucci A; Martin SE; Khan A; Mathelier A; Thiede B; Walker S; Mills IG
Theranostics; 2019; 9(8):2183-2197. PubMed ID: 31149037
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CDK9 activity compromises global splicing in prostate cancer cells.
Hu Q; Poulose N; Girmay S; Helevä A; Doultsinos D; Gondane A; Steele RE; Liu X; Loda M; Liu S; Tang DG; Mills IG; Itkonen HM
RNA Biol; 2021 Nov; 18(sup2):722-729. PubMed ID: 34592899
[TBL] [Abstract][Full Text] [Related]
7. Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis.
Lynch TP; Ferrer CM; Jackson SR; Shahriari KS; Vosseller K; Reginato MJ
J Biol Chem; 2012 Mar; 287(14):11070-81. PubMed ID: 22275356
[TBL] [Abstract][Full Text] [Related]
8. Identification of a diketopiperazine-based O-GlcNAc transferase inhibitor sensitizing hepatocellular carcinoma to CDK9 inhibition.
Shan X; Jiang R; Gou D; Xiang J; Zhou P; Xia J; Wang K; Huang A; Tang N; Huang L
FEBS J; 2023 Sep; 290(18):4543-4561. PubMed ID: 37247228
[TBL] [Abstract][Full Text] [Related]
9. CDK9 inhibition strategy defines distinct sets of target genes.
Garriga J; Graña X
BMC Res Notes; 2014 May; 7():301. PubMed ID: 24886624
[TBL] [Abstract][Full Text] [Related]
10. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells.
Itkonen HM; Minner S; Guldvik IJ; Sandmann MJ; Tsourlakis MC; Berge V; Svindland A; Schlomm T; Mills IG
Cancer Res; 2013 Aug; 73(16):5277-87. PubMed ID: 23720054
[TBL] [Abstract][Full Text] [Related]
11. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
Caracciolo V; Laurenti G; Romano G; Carnevale V; Cimini AM; Crozier-Fitzgerald C; Gentile Warschauer E; Russo G; Giordano A
Cell Cycle; 2012 Mar; 11(6):1202-16. PubMed ID: 22391209
[TBL] [Abstract][Full Text] [Related]
12. A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine.
Walsby E; Pratt G; Shao H; Abbas AY; Fischer PM; Bradshaw TD; Brennan P; Fegan C; Wang S; Pepper C
Oncotarget; 2014 Jan; 5(2):375-85. PubMed ID: 24495868
[TBL] [Abstract][Full Text] [Related]
13. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.
Hou T; Ray S; Brasier AR
J Biol Chem; 2007 Dec; 282(51):37091-102. PubMed ID: 17956865
[TBL] [Abstract][Full Text] [Related]
14. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
15. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1.
Caldwell SA; Jackson SR; Shahriari KS; Lynch TP; Sethi G; Walker S; Vosseller K; Reginato MJ
Oncogene; 2010 May; 29(19):2831-42. PubMed ID: 20190804
[TBL] [Abstract][Full Text] [Related]
16. CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation.
Itkonen HM; Poulose N; Walker S; Mills IG
Neoplasia; 2019 Jul; 21(7):713-720. PubMed ID: 31151054
[TBL] [Abstract][Full Text] [Related]
17. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
[TBL] [Abstract][Full Text] [Related]
18. Evidence of the involvement of O-GlcNAc-modified human RNA polymerase II CTD in transcription in vitro and in vivo.
Ranuncolo SM; Ghosh S; Hanover JA; Hart GW; Lewis BA
J Biol Chem; 2012 Jul; 287(28):23549-61. PubMed ID: 22605332
[TBL] [Abstract][Full Text] [Related]
19. Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.
Phillipson LJ; Segal DH; Nero TL; Parker MW; Wan SS; de Silva M; Guthridge MA; Wei AH; Burns CJ
Bioorg Med Chem; 2015 Oct; 23(19):6280-96. PubMed ID: 26349627
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
